KURA - Kura Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.54
+0.27 (+2.91%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.27
Open9.05
Bid9.09 x 800
Ask9.70 x 800
Day's Range8.80 - 9.81
52 Week Range6.35 - 21.42
Volume403,524
Avg. Volume316,161
Market Cap433.383M
Beta (5Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-1.50
Earnings DateFeb 24, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.14
  • Thomson Reuters StreetEvents

    Edited Transcript of KURA earnings conference call or presentation 25-Feb-20 9:30pm GMT

    Q4 2019 Kura Oncology Inc Earnings Call

  • Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas
    GlobeNewswire

    Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype. “This important designation from the FDA comes just two months after tipifarnib was awarded Fast Track for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC),” said Bridget Martell, M.A., M.D., Acting Chief Medical Officer of Kura Oncology.

  • Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
    GlobeNewswire

    Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results

    – Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company.

  • Kura Oncology to Participate in Three Upcoming Investor Conferences
    GlobeNewswire

    Kura Oncology to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, Feb. 19, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results
    GlobeNewswire

    Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results

    SAN DIEGO, Feb. 18, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study
    Benzinga

    The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (NASDAQ: ...

  • Kura Oncology Announces Transition of Chief Medical Officer
    GlobeNewswire

    Kura Oncology Announces Transition of Chief Medical Officer

    – Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and.

  • 3 Healthcare Stocks That Can Double in the Next Year
    TipRanks

    3 Healthcare Stocks That Can Double in the Next Year

    Risk and reward are two of the most commonly used words in investing. The two are symbiotic and complement each other perfectly. Where there is more risk, the reward is likely to be more abundant. Of course, the equation works the other way too: less risk, probably less reward.The thesis is simple: a company such as Google is likely a pretty safe place for an investment. But with a market cap of $1 trillion, how much value can the company add to its share price? On the other hand, investing in a fledgling biotech with life-changing treatments in the pipeline could potentially see an investment yield extraordinary returns. Let’s not forget, though, this sort of investment also carries a significant amount of risk with it.With this in mind, TipRanks’ Stock Screener pointed us in the direction of three Healthcare stocks the experts on the Street think could soar in the year ahead. And by soar, we mean at least double their current value. The risk here as an investor is higher, but as we know by now, so are the possible rewards. As an added bonus, all three currently have a Strong Buy consensus rating from the Street. Let’s take a look at the data.ProQR Therapeutics (PRQR)ProQR’s back story is unusual. The company was founded after CEO Daniel de Boer’s newborn son was diagnosed with cystic fibrosis. De Boer, with the help of several co-founders, then formed ProQR – a biotech with a focus on providing new medicines for rare diseases. There are approximately 7,000 rare diseases in the world today, and only 400 currently have treatments, a situation ProQR hopes to change with the use of RNA therapies.The company has a diverse portfolio of therapies all in different stages of development. Among these are Sepofarsen, a treatment for Leber congenital amaurosis (LCA-10), the most common genetic cause of childhood blindness. Sepofarsen works by repairing the genetic defect in the RNA, with it standing to fill a gap as there aren’t any approved treatments available. The FDA and EMA have granted the drug orphan designation, and top-line data from the on-going Phase 2/3 Illuminate trial is expected during the first half of 2021. The company is also developing QR-421a, a treatment for Usher syndrome, a rare genetic disease that is the main cause for combined blindness and deafness. It should be noted that the therapy has been granted fast track designation by the FDA.Evercore’s Joshua Schimmer is impressed with Sepofarsen’s results so far. The 5-star analyst explained, “We saw 12 month data help confirm the durability of treatment effect in the pivotal Phase 2/3 dose through 12 months. The strong responses were maintained across visual acuity, mobility and sensitivity endpoints. The Phase 1/2 results bode well for the Phase 2/3 and may help validate the other pipeline opportunities… We remain encouraged by the LCA10 12-month data and see read-through to other larger indications.”Therefore, Schimmer reiterated an Outperform rating on PRQR, along with a price target of $34. Should the target be met, investors stand to pocket a massive 323% 12-month gain. (To watch Schimmer’s track record, click here)The Street is equally confident in the rare disease fighter’s ability to soar over the next 12 months. A Strong Buy analyst consensus is formed of Buy ratings only, 5 to be precise. The average price target is $28.80 and indicates possible upside of 258%. (See ProQR stock analysis on TipRanks) Cellectis SA (CLLS)French gene-editing pioneer Cellectis has been turning heads recently with its novel approach to cancer treatment.The company has developed a gene-editing technology called TALEN and has been making deals with fellow companies to advance effective cancer therapies. It recently announced a deal with Iovance Biotherapeutics, to which Cellectis has granted exclusive global rights for the use of its gene-editing technology to edit a series of cancer treatments known as tumor-infiltrating lymphocytes, or TILs. Cellectis, in return, will receive royalties on sales of gene-edited TILs from Iovance along with development and sales milestone payments.Cellectis also has deals with French pharmaceutical company Servier. The two are collaborating on five targets, including UCART19, a cellular therapy candidate against lymphoid malignancies progressing through trials. Additionally, Cellectis has a partnership with cancer-focused biotech Allogene. The company has been granted a license from Cellectis for the development of ALLO-501, a similar treatment to UCART19 but manufactured using a different process. Phase 1 has started in relapsed/refractory non-Hodgkin lymphoma.Nomura’s Christopher Marai believes Cellectis remains “grossly undervalued vs. peers.” The 4-star analyst noted, “We estimate that even a modest 8x on $80 million in potential royalties (estimate 8% royalties on sales, and up to $185 million in milestones per target) is justified by ALLO’s valuation (that incorporates mostly ALLO-501, in our view). This suggests that UCART19 alone should be worth $640 million in enterprise value to CLLS, or $15/share alone. This does not consider the 69.1% stake in Calyxt (~$125 million enterprise value).”What does this mean, then? It means Marai is bullish on CLLS. The analyst reiterated a Buy rating on Cellectis alongside a price target of $73. Should the figure be met, gains of 300% could be in the cards over the next year. (To watch Marai’s track record, click here)And what does the rest of the Street reckon 2020 has in store for the gene-editing company? Upside is the answer – Cellectis’ Strong Buy consensus rating breaks down into 4 Buys and 1 Hold. The average price target is $42.75 and implies a possible 12-month rise of 134%. (See Cellectis stock analysis on TipRanks) Kura Oncology (KURA)Kura is another biotech fighting the good fight against cancer. The company is focused on treatments for solid tumors and blood cancers, with several candidates in the pipeline.All eyes, though, are currently on the company’s lead candidate, Tipifarnib, an oral nonpeptidomimetic farnesyl transferase inhibitor. It can be used in both solid tumors and hematologic malignancies such as acute myeloid leukemia. The drug is presently in various stages of development for the treatment of several indications, and was recently granted fast track designation by the FDA for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC).Last month, Kura presented data from its ongoing Phase 2 trial for tipifarnib in peripheral T-cell lymphoma (PTCL) at the American Society of Hematology (ASH). Deutsche Bank’s Konstantinos Aprilakis came away impressed. The analyst stated, “We see the impressive clinical efficacy presented for tipifarnib in AITL at ASH as well as the positive regulatory guidance, especially the low bars for success in the pivotal trial, as encouraging for the company and supportive of an accelerated path forward for tipifarnib in the setting of blood cancers.”To this end, Aprilakis left a Buy rating and price target of $28 unchanged, implying upside potential of a handsome 119%. (To watch Aprilakis’ track record, click here)Other members of the Street are with the Deutsche analyst on Kura. 4 Buy recommendations from analysts tracked over the last three months add up to a Strong Buy consensus rating. The average price target comes in at $29.50 and indicates potential upside of 131%. (See Kura stock analysis on TipRanks)

  • Kura Oncology to Present at J.P. Morgan Healthcare Conference
    GlobeNewswire

    Kura Oncology to Present at J.P. Morgan Healthcare Conference

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Thursday, January 16, 2020 at 10:00 a.m. PT / 1:00 p.m. ET, followed by a Q&A session at 10:30 a.m. PT / 1:30 p.m. ET. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

  • Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
    GlobeNewswire

    Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers as Chief Commercial Officer. Ms. Flowers joins Kura most recently from Array Biopharma, where she served as head of commercial operations until the completion of its $11.4 billion acquisition by Pfizer in July 2019. “Kirsten is a world-class leader in building successful commercial organizations and launching precision medicines for the treatment of cancer,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
    GlobeNewswire

    Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC) after progression on platinum therapy. “We are very encouraged by our growing body of clinical data for tipifarnib in HRAS mutant HNSCC and believe that the FDA’s Fast Track designation puts us one step closer to delivering a precision medicine treatment for patients with this devastating disease,” said Antonio Gualberto, M.D., Ph.D., Head of Development and Chief Medical Officer of Kura Oncology.

  • Kura Oncology, Inc. (KURA): Hedge Funds Can’t Make Up Their Minds
    Insider Monkey

    Kura Oncology, Inc. (KURA): Hedge Funds Can’t Make Up Their Minds

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
    GlobeNewswire

    Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

    – Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR).

  • Kura Oncology to Participate in Piper Jaffray Healthcare Conference
    GlobeNewswire

    Kura Oncology to Participate in Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 26, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • Kura Oncology Requires Plenty of Patience by Investors
    TheStreet.com

    Kura Oncology Requires Plenty of Patience by Investors

    During the Lightning Round segment of Mad Money Friday night one caller inquired about Kura Oncology : "This has personalized cancer treatments and I like it for speculation," said Jim Cramer. In the daily bar chart of KURA, below, we can see that prices are showing us two trends. The daily On-Balance-Volume (OBV) line shows a decline into early October and then a rise.

  • Thomson Reuters StreetEvents

    Edited Transcript of KURA earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Q3 2019 Kura Oncology Inc Earnings Call

  • Kura Oncology to Present at Stifel Healthcare Conference
    GlobeNewswire

    Kura Oncology to Present at Stifel Healthcare Conference

    SAN DIEGO, Nov. 12, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • Hedge Funds Have Never Been This Bullish On Kura Oncology, Inc. (KURA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Kura Oncology, Inc. (KURA)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]

  • Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
    GlobeNewswire

    Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting

    SAN DIEGO, Nov. 06, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
    GlobeNewswire

    Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of.

  • Kura Oncology Appoints James Basta as Chief Legal Officer
    GlobeNewswire

    Kura Oncology Appoints James Basta as Chief Legal Officer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of James Basta as Chief Legal Officer and Corporate Secretary. Mr. Basta will also serve as the Company’s Chief Compliance Officer. “We are privileged to have an executive of Jim’s caliber join our senior leadership team,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • Kura Oncology to Report Third Quarter 2019 Financial Results
    GlobeNewswire

    Kura Oncology to Report Third Quarter 2019 Financial Results

    SAN DIEGO, Oct. 30, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
    GlobeNewswire

    Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today reported updated data from a Phase 2 clinical trial of its lead drug candidate, tipifarnib, that show durable anti-tumor activity as a single agent in heavily pretreated patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC). As of the October 17, 2019 data cutoff date, a total of 21 HNSCC patients with high HRAS mutant variant allele frequency1 were enrolled in this Phase 2 trial (RUN-HN), of whom 18 were evaluable for efficacy. Ten of the 18 evaluable patients achieved a confirmed partial response (PR), as defined by standard RECIST criteria, for an objective response rate (ORR) of 56% (95% CI 0.31, 0.78).

  • Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    GlobeNewswire

    Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    – Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th – –.

  • Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    GlobeNewswire

    Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    SAN DIEGO, Oct. 16, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.